A Japanese health ministry proposal to impose steeper price cuts on certain medicines deemed to carry poor cost-effectiveness profiles cleared…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY Moderna COVID-19 Booster Up for Panel Review on Dec. 15
December 9, 2021
-
REGULATORY MHLW Warns against Hoarding on 17 APIs as Hitachi Fire Stirs Supply Worries
December 8, 2021
-
BUSINESS EU Panel Backs Tocilizumab for Severe COVID-19: Chugai
December 8, 2021
-
BUSINESS Horizon Plants Flag in Japan Soil to Gear Up for Thyroid Eye Disease Trial
December 7, 2021
-
REGULATORY BMS’ Second CAR-T Therapy Ide-Cel in Line for Approval in January
December 7, 2021
-
BUSINESS Towa Bags Approval of Edirol AG through Partial Change of Its Version
December 7, 2021
-
REGULATORY Panel OKs Outline of Emergency Approval System Based on “Presumed” Efficacy
December 6, 2021
-
REGULATORY MOF Panel’s Budget Proposal Pushes Macroeconomic Indexing, No Adjustment Rate
December 6, 2021
-
BUSINESS MSD Files Oral COVID-19 Drug in Japan
December 3, 2021
-
REGULATORY Average NHI-Market Price Gap of Listed Drugs at 7.6%: MHLW
December 3, 2021
-
REGULATORY Chuikyo Members Call for Restrictions in Re-Pricing Exclusions from Spillover Rule
December 2, 2021
-
BUSINESS Blaze at Hitachi Logistic Center Could Add to Drug Supply Woes
December 1, 2021
-
REGULATORY Japan Confirms 1st Case of Omicron Variant: MHLW
December 1, 2021
-
REGULATORY Alzheimer’s Drugs in Mind, MHLW to Float New Rule for Potential Super Big Sellers
November 30, 2021
-
BUSINESS Takeda’s GI Biz Poised for Growth with 3 Products Now in Its Lineup
November 29, 2021
-
REGULATORY Japan Approves Jardiance for Heart Failure, Label Expansions for Opdivo and Keytruda
November 26, 2021
-
REGULATORY Pharma Pushes 2% Adjustment Rate Plus Certain Range in 2022 Drug Price Revision
November 26, 2021
-
REGULATORY Sanofi’s Praluent to Be Taken Off Japan NHI Price List Next Spring
November 26, 2021
-
REGULATORY LDP Health Panel Chief Vows to Push Development of Japan-Made Vaccines and Drugs
November 25, 2021
-
BUSINESS Top 3 Japan Generic Makers Face Uphill Struggle Overseas in April-September: Jiho Tally
November 25, 2021
ページ
A Japanese drug pricing panel on November 11 discussed ways to respond to the US most-favored-nation (MFN) policy, with healthcare…
On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…